Lifebit Biotech Ltd.

Key Facts

Lifebit is creating a world where access to biomedical data will never be an obstacle to curing diseases​. Our patented federated technology solves the biggest roadblock for precision medicine – making sensitive data of biobanks, universities, governments, and healthcare providers securely accessible by bringing researcher’s analysis and computation to where the data resides, instead of moving the data.

Successes in UK/NHS

In March 2020, the UK Government formed a consortium with the world’s leading science and technology partners to enable research on COVID-19 data to inform vaccines and treatments. Lifebit was selected as the provider of the secure, scalable and collaborative Trusted Research Environment of the UK Government agency, Genomics England. This enabled global pharma companies, researchers and clinicians with secure access and analysis of Genomics England’s 135,000-strong cohort of COVID-19, cancer and rare undiagnosed disease patient’s whole genome data. The platform is central to the UK Government’s research response to COVID-19.

Company details

Solutions

Driving insights and analysis

Specialism

Data platforms & environments

Drug discovery and Clinical trials

Company details

Want to connect with this innovator?

Make an enquiry

Website

lifebit.ai/

Markets already exporting to

Major Clients in: US (The Jackson Laboratory), Germany (Boehringer Ingelheim), UK (Genomics England, the University of Cambridge, Flatiron Health), Denmark (the Danish National Genome Center), Greece (BeginNGS), Mexico (Omica.bio) and Brazil (Gen-t).

Desired Markets

While we are a global company, we see a key focus for population genomics and precision medicine initiatives in the US, Canada, France, Nordics, Estonia, Gulf States, Singapore, Thailand, Japan, and Australia

Desired customer types

Lifebit seeks to partner with Data Custodians who want to make large-scale health data securely available for research and commercialisation, which includes 1) Government funded national population genomic initiatives/precision medicine programs 2) Large private or university biobanks 3) Large healthcare providers 4) Data Consumers that need access to large-scale biomedical datasets for R&D and drug discovery purposes 5) Pharmaceutical companies (EMEA, US, Japan) 6) Large biotechs

Want to connect with this innovator?
Make an enquiry
Close
This field is required
This field is required
This field is required
This field is required
This field is required

Thank you

We are processing your request and will return your contact as soon as possible.